Last $0.72 USD
Change Today +0.068 / 10.43%
Volume 1.5M
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.67
Previous Close
$0.65
Day High
$0.72
Day Low
$0.65
52 Week High
03/5/14 - $0.97
52 Week Low
06/26/13 - $0.23
Market Cap
152.8M
Average Volume 10 Days
3.8M
EPS TTM
$-0.05
Shares Outstanding
212.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a drug-medical device and therapeutic company, designs, develops, and commercializes medical approaches for the treatment of solid tumors in the United States. The company is developing technology based on the proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Its clinical programs include three Phase II clinical trials to assess the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions, Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

12 Employees
Last Reported Date: 12/10/13

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $390.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $247.2K
Compensation as of Fiscal Year 2013.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 11:20 AM

OncoSec Medical Incorporated Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 11:20 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

OncoSec Medical Incorporated Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:00 PM

OncoSec Medical Incorporated Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:00 PM. Venue: New York Academy of Sciences, New York, United States.

OncoSec Medical Incorporated to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial

OncoSec Medical Incorporated announced that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study. The protocol addendum will allow for the assessment of the safety and efficacy of a six-week treatment cycle with ImmunoPulse in up to 21 melanoma patients. Each cycle will consist of treatments on Days 1, 8 and 15. Subjects will be eligible for an additional cycle as early as six weeks from the first treatment up to a maximum of nine treatment cycles. The protocol addendum will provide an opportunity to assess whether more frequent treatment with ImmunoPulse can provide additional clinical benefit to melanoma patients. The protocol addendum is also intended to help optimize the treatment design of the Company's Phase IIb study in melanoma patients, which is expected to initiate in late 2014. Safety of this intensified dose regimen will also be assessed. In the current trial design, subjects are eligible to receive one treatment cycle every 12 weeks. Based on interim analysis through Day 180 of the first 21 subjects, it was shown that 38.1% (eight out of 21) of patients achieved an objective overall response by modified RECIST v1.1, defined as a >= 30% reduction in the summed size of lesions. At the time of this interim analysis, six patients (28.6%) had demonstrated a partial response, and two patients (9.5%) had achieved a complete response, lasting at least six months. An additional 9.5% (two out of 21) of patients exhibited clinically beneficial disease stabilization for at least three months. Moreover, no treatment-related severe adverse events (SAEs) were reported and there were no adverse events (AEs) greater than grade two, and AEs were generally limited to transient pain related to electroporation treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.72 USD +0.068

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.